

- **Name:** Zhuoran Yao
  - **Current Position & Affiliation:** Thoracic Cancer Ward, Cancer Center, West China Hospital, Sichuan University
  - **Country:** China
- 

• **Educational Background:**

MD, Peking Union Medical College (School of Medicine)  
BSc, Tsinghua University (School of Life Science)

• **Professional Experience:**

Residencies, West China Hospital, Sichuan University  
Post-Doc, Clinical Cell Therapy Lab, West China Hospital, Sichuan University  
Visiting Scholar, School of Medicine, Duke University

• **Professional Organizations:**

Member of CSCO (Chinese Society of Clinical Oncology)  
Member of IASLC (International Association for the Study of Lung Cancer)

• **Main Scientific Publications:**

Successful Pregnancy and Healthy Baby Outcome in a Patient With Tyrosine Kinase Inhibitor-Refractory ALK-Positive NSCLC and Central Nervous System Metastasis Treated With Lorlatinib With Maternal-Fetal Pharmacokinetics and Child Milestone Development Correlations. J Thorac Oncol. 2025 (Co-first author)

STING Agonist Synergistically Amplifies PD-1 Blockade and Radiation-induced Systemic Anti-tumor Responses via Tumor Microenvironment Enrichment. International Journal of Radiation Oncology • Biology • Physics. 2025 (Co-corresponding author)

Nervous system contributions to small cell lung cancer: Lessons from diverse oncological studies. Biochim Biophys Acta Rev Cancer. 2025. (Co-corresponding author)

Preclinical study and phase II trial of adapting low-dose radiotherapy to immunotherapy in small cell lung cancer. Med. 2024. (Co-first author)

Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naive Stage IV PD-L1+ Non-Small-Cell Lung Cancer Patients. Clin Cancer Res. 2023. (Co-first author)

Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. Lancet Oncol. 2021. (Co-first author)

Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis

sis. BMC Med. 2020. (Co-first author)